Study guide

2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy

Key Takeaways Explain This Topic AI

First-line pharmacotherapy for nausea and vomiting of pregnancy is pyridoxine 10 to 25 mg three to four times daily, alone or with doxylamine 10 to 12.5 mg three to four times daily.

Hyperemesis gravidarum is distinguished from ordinary nausea and vomiting by more than 5 percent loss of prepregnancy weight, ketonuria of 2+ or greater, and hypokalemic hypochloremic metabolic alkalosis.

Intravenous thiamine 100 mg must be given before or with dextrose infusion in prolonged vomiting to prevent Wernicke encephalopathy.

Reflux treatment escalates from dietary and positional change to calcium carbonate antacids, then famotidine, then a proton pump inhibitor, with sucralfate as a minimally absorbed option.

Castor oil and mineral oil are avoided for constipation in pregnancy because castor oil provokes uterine contractions and mineral oil impairs absorption of vitamins A, D, E, and K.

Last updated: September 2026

Rising hCG and estrogen, and the smooth-muscle relaxation produced by progesterone, account for most of the gastrointestinal complaints of pregnancy. The midwifery approach is to validate the experience, treat it in evidence-based steps, and stay alert for the point at which a common discomfort has become a pathology — most importantly, the transition from ordinary nausea and vomiting to hyperemesis gravidarum.

Nausea and Vomiting of Pregnancy (NVP) & Hyperemesis Gravidarum

Nausea and vomiting of pregnancy affects up to 70–80% of pregnant individuals. Symptoms characteristically commence between 4 and 6 weeks gestation, peak between 8 and 10 weeks, and resolve spontaneously in over 85% of patients by 16 to 20 weeks.

Pathophysiological Drivers

Rapidly rising levels of human chorionic gonadotropin (hCG) and estrogen , which stimulate the chemoreceptor trigger zone in the brainstem.

Elevated progesterone , which relaxes gastrointestinal smooth muscle, prolongs gastric emptying time, and impairs gastrointestinal motility.

Genetic factors involving the growth differentiation factor 15 ( GDF15 ) gene and vestibular hypersensitivity.

Clinical Severity: PUQE Score vs. Hyperemesis Gravidarum

Midwives quantify symptom severity using the validated Pregnancy-Unique Quantification of Emesis (PUQE) score, evaluating: (1) hours of nausea per day, (2) daily vomiting episodes, and (3) daily retching/dry-heaving episodes.

PUQE Score: Mild (≤6 points), Moderate (7–12 points), Severe (≥13 points).

  • Diagnostic Feature Mild to Moderate NVP Hyperemesis Gravidarum (HG)
  • Maternal Weight Change Stable or minimal loss (<5% prepregnancy weight) >5% loss of prepregnancy weight

Hydration & Oral Intake Tolerates sips of fluids and bland snacks Intractable vomiting; unable to retain liquids for >24 hours

  • Urine Ketones Negative or trace Moderate to large ketonuria (≥2+)
  • Electrolyte Balance Normal serum electrolytes Hypokalemia, hyponatremia, hypochloremic metabolic alkalosis

Hepatic / Renal Labs Normal AST/ALT, BUN, and creatinine Mild transaminitis (AST/ALT <3x normal), elevated BUN/Cr, hemoconcentration

  • Stepwise Management of NVP NVP Stepwise Management Pathway
  • ├── Step 1: Dietary & Lifestyle Modifications
  • │ ├── Small, frequent meals q1-2h (high protein, dry carbohydrates)
  • │ ├── Acupressure wristbands at Neiguan (P6) point + Ginger (250 mg PO QID)
  • │ └── Discontinue prenatal vitamins containing iron; substitute folic acid alone
  • ├── Step 2: First-Line Pharmacotherapy (ACOG Level A)
  • │ └── Pyridoxine (Vitamin B6) 10-25 mg PO TID/QID + Doxylamine 10-12.5 mg PO TID/QID
  • ├── Step 3: Second-Line Antiemetic Escalation
  • │ ├── Add Promethazine (12.5-25 mg PO/PR q4-6h) OR Prochlorperazine (5-10 mg PO/PR q6-8h)
  • │ └── OR Metoclopramide (5-10 mg PO/IV q8h - dopamine antagonist with prokinetic action)
  • └── Step 4: Third-Line & Refractory Hyperemesis
  • ├── Ondansetron (4-8 mg PO/IV q8h - serotonin 5-HT3 antagonist)
  • └── Inpatient IV rehydration: D5LR/D5NS + IV THIAMINE (100 mg) BEFORE DEXTROSE

Caution

Wernicke Encephalopathy Prevention: In patients with prolonged vomiting or hyperemesis gravidarum, maternal thiamine (Vitamin B1) stores are rapidly depleted. Intravenous infusion of glucose/dextrose without thiamine triggers acute cerebral pyruvate accumulation, causing Wernicke encephalopathy (triad of ataxia, ophthalmoplegia, and acute confusion). Always administer 100 mg IV thiamine prior to or concurrent with dextrose infusions .

  • Gastrointestinal Discomforts: GERD, Constipation & Hemorrhoids
  • Gastroesophageal Reflux Disease (GERD / Pyrosis)

Etiology: Progesterone decreases the resting basal tone of the lower esophageal sphincter (LES) and slows gastric transit. In the late second and third trimesters, the expanding gravid uterus elevates intra-abdominal pressure, displacing the stomach cephalad and promoting acid reflux.

Midwifery Interventions:

Non-Pharmacologic: Small, frequent meals; avoid eating within 2 to 3 hours of recumbency; elevate the head of the bed 6 inches using a wedge pillow; eliminate trigger foods (caffeine, chocolate, peppermint, citrus, acidic, and high-fat foods); avoid tight, restrictive abdominal clothing.

First-Line Pharmacologic: Calcium carbonate antacids (e.g., Tums; provides both symptom relief and bioavailable calcium). Avoid sodium bicarbonate (risk of systemic metabolic alkalosis and fluid retention) and high-dose magnesium trisilicate.

Second-Line Pharmacologic: Histamine-2 receptor antagonists (H2RAs) : Famotidine (20–40 mg daily or BID).

Third-Line Pharmacologic: Proton pump inhibitors (PPIs) : Omeprazole (20 mg daily) or pantoprazole for refractory erosive symptoms.

Mucosal Protectant: Sucralfate (1 g PO TID/QID; minimally absorbed systemically, highly safe).

Constipation

Etiology: Progesterone inhibits gastrointestinal motilin and reduces colonic smooth muscle contractility, doubling colonic transit time and maximizing mucosal water reabsorption. Ingestion of supplemental elemental iron and mechanical rectosigmoid compression by the fetal head compound the issue.

Midwifery Interventions:

Lifestyle: Increase dietary fiber intake to 25 to 30 grams/day (legumes, whole grains, fruits, vegetables, prunes); increase daily oral hydration to 2.5 to 3.0 liters/day (8–10 glasses); engage in daily moderate physical exercise.

First-Line Laxatives: Bulk-forming laxatives ( psyllium husk , methylcellulose) and surfactant stool softeners ( docusate sodium 100 mg PO BID).

Second-Line Laxatives: Osmotic agents such as polyethylene glycol (PEG 3350 / MiraLAX) 17 g daily, lactulose, or magnesium hydroxide (Milk of Magnesia).

Contraindicated / Avoid: Stimulant laxatives like castor oil (provokes violent uterine contractions and diarrhea) and mineral oil (impairs fat-soluble vitamin A, D, E, K absorption).

Hemorrhoids

Etiology: Progesterone-induced venodilation combined with mechanical obstruction of the inferior vena cava and iliac veins markedly increases hemorrhoidal venous plexus pressure, exacerbated by chronic straining during defecation.

Management: Prevention of hard stools; warm sitz baths for 15–20 minutes twice daily; application of cold ice packs; topical astringents ( witch hazel pads / Tucks ); topical hydrocortisone 1% cream combined with pramoxine for acute pruritus and inflammation; gentle manual reduction of prolapsed external hemorrhoids.

Loading diagram... Stepwise Clinical Algorithm for Nausea and Vomiting of Pregnancy